2019
Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2012
The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care 2012, 35: 690-692. PMID: 22374642, PMCID: PMC3308292, DOI: 10.2337/dc11-0732.Peer-Reviewed Original ResearchConceptsType 1 diabetesDetemir insulinInsulin analoguesInsulin pharmacodynamicsRapid-acting insulin analoguesRapid-acting insulinTime-action profileEuglycemic glucose clampCommon regimenRandomized studyDaily injectionsUnits/Glucose clampInsulin actionSame syringePharmacodynamicsAspartInsulinDiabetesRandom orderAdverse effectsSeparate injectionsAction studiesInjectionMixed injection
2011
A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus
Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV. A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. Endocrine Practice 2011, 17: 862-866. PMID: 21550949, DOI: 10.4158/ep11031.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated HemoglobinHospitals, PediatricHospitals, UniversityHumansHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulin DetemirInsulin Infusion SystemsInsulin, IsophaneInsulin, Long-ActingInsulin, Short-ActingMaleConceptsRapid-acting insulin analoguesInsulin detemirNPH insulinYounger patientsA1c levelsInitial treatmentInsulin dosesNew-onset type 1 diabetes mellitusInsulin analoguesBasal/bolus insulinTotal daily insulin dosesType 1 diabetes mellitusInsulin injection treatmentPump-treated patientsDaily insulin dosesHemoglobin A1c levelsTwice daily regimenEffective initial treatmentSevere hypoglycemic eventsNew-onset T1DMInsulin pump therapyDetemir insulinDaily regimenInsulin regimenDiabetes mellitus
2010
Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes
Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010, 33: 1009-1012. PMID: 20150302, PMCID: PMC2858163, DOI: 10.2337/dc09-2118.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose clamp studiesGlucose excursionsClamp studiesMeal-related glucose excursionsRapid-acting insulin analoguesRapid-acting insulinEuglycemic glucose clampTime-action curvePharmacodynamic peakA1c levelsTreatment burdenPharmacodynamic effectsDaily injectionsUnits/Pharmacodynamic actionClinical studiesGlucose clampMixed injectionGlargineEarly pharmacokineticsInsulin analoguesObjective clinicianInsulin pharmacokineticsLispro
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseChildDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInjectionsInsulinInsulin GlargineInsulin, IsophaneInsulin, Long-ActingConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetesInsulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2008, 153: 547-553.e3. PMID: 18589448, DOI: 10.1016/j.jpeds.2008.04.063.Peer-Reviewed Original ResearchConceptsInsulin glargineMultiple daily injectionsMultiple daily injection regimensType 1 diabetes mellitusBaseline A1C valuesDaily insulin glargineParallel group comparisonIntermediate acting insulinIntermediate-acting insulinOccurrence of hypoglycemiaPrandial insulin lisproOverall mean changeElevated A1C.MDI regimenMDI regimensBaseline A1CInjection regimensWeek 24Adverse eventsDiabetes mellitusHemoglobin A1cPediatric patientsSevere hypoglycemiaDaily injectionsA1C values
2007
FreeStyle Navigator Continuous Glucose Monitoring System Use in Children With Type 1 Diabetes Using Glargine-Based Multiple Daily Dose Regimens Results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group
Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. FreeStyle Navigator Continuous Glucose Monitoring System Use in Children With Type 1 Diabetes Using Glargine-Based Multiple Daily Dose Regimens Results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Care 2007, 31: 525-527. PMID: 18096811, PMCID: PMC2365493, DOI: 10.2337/dc07-1995.Peer-Reviewed Original Research
2004
A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine
Doyle (Boland) E, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine. Diabetes Care 2004, 27: 1554-1558. PMID: 15220227, DOI: 10.2337/diacare.27.7.1554.Peer-Reviewed Original ResearchConceptsTotal daily insulin doseMultiple daily injectionsType 1 diabetesWeeks of therapyGlargine groupDaily injectionsInsulin aspartMDI treatmentShort-term studiesContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseDaily insulin doseSelf-monitored blood glucose measurementsInsulin infusion therapySubcutaneous insulin infusionBlood glucose readingsSelf-monitored blood glucose readingsBlood glucose measurementsDaily glargineCSII groupDose titrationProspective trialAdverse events